Introduction:
Merck plans to invest US$324 million (€300 mn) to open new bioprocessing production centre for the development of biologics in Daejeon, South Korea.
Features:
The new centre spanning across 43,000 square metres, will serve as a comprehensive hub housing cutting-edge production capabilities, a distribution centre, and an automated warehouse.
This state-of-the-art bioprocessing production centre is poised to deliver indispensable biotechnological products, ranging from dry powder cell culture media to process liquids, pre-GMP small-scale manufacturing, and sterile sampling systems.
The facility will play a pivotal role in facilitating various stages of biologics production, from process development and clinical research to commercial manufacturing. In addition, it will serve biotech and pharmaceutical firms in the development of processes, conducting clinical research, and the commercial production of biologic drugs.
The new site represents the largest investment in the Asia-Pacific region, enhancing its capabilities in life science division. This investment is projected to generate approximately 300 new jobs by the end of 2028.
Specifications:
Name MilliporeSigma
Type New Construction
Budget US$324 million (€300 mn)
Year 2028
